Highmark sues University of Pittsburgh Medical Center, claims $300M cancer drug overbilling
Health insurer Highmark Inc. has sued the University of Pittsburgh Medical Center claiming the hospital network has overbilled it by $300 million for cancer drugs.
Highmark sues University of Pittsburgh Medical Center, claims $300M cancer drug overbilling
Health insurer Highmark Inc. has sued the University of Pittsburgh Medical Center claiming the hospital network has overbilled it by $300 million for cancer drugs.
Pennsylvania Insurance Department, Highmark spell out coverage plan after UPMC split
Health insurer Highmark Inc. and the Pennsylvania Insurance Department have spelled out a plan for Highmark customers to continue using doctors and some hospitals from the rival University of Pittsburgh Medical Center once Highmark's provider agreement with UPMC ends Jan. 1.
Louisiana attorney general sues State Farm, accusing insurer of unsafe auto repair practices
Attorney General Buddy Caldwell filed a lawsuit Tuesday against State Farm, alleging Louisiana's largest auto insurer is illegally steering customers involved in car accidents to repair shops that use junkyard parts and choose cheap fixes over safety.
Allergan sues rival drugmaker Valeant and partner, alleging fraud in hostile takeover attempt
Botox maker Allergan is suing a Canadian drugmaker and a hedge fund over their hostile takeover attempt, alleging insider trading and other fraud before their plan became public.
Despite outcry over cost, breakthrough drug becomes treatment of choice for hepatitis C
A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.
Aetna 2Q profit increases 2.4 percent, tops forecast
Aetna Inc. (AET) on Tuesday reported profit that climbed by 2.4 percent in its second quarter, and topped analysts' expectations.
Virus drugmaker fights back against pediatricians group's limits on medicine use for preemies
A costly drug given mostly to premature babies is at the center of a clash between the manufacturer and the nation's leading pediatrician's group, which recommends scaling back use of the medicine.
Faith-affiliated nonprofits' contraceptive challenge is next health law case for Supreme Court
How much distance from an immoral act is enough?
Anthem seeks 12.5 percent rate increase; opponents call request 'exorbitant'
Consumers and advocates urged state insurance regulators on Friday to deny a 12.5 percent rate increase proposed by Anthem Blue Cross and Blue Shield, Connecticut's largest health insurer.
AIG Swings to Loss on Lower Investment Income
American International Group Inc. swung to loss in the third quarter, falling short of Wall Street expectations as the giant insurer faces calls from shareholders Carl Icahn and John Paulson to break up.
Jefferies' Sage Kelly Resigns from Post Amid Scandal
Embattled Jefferies and Co. investment banker Sage Kelly has resigned amid a messy scandal.
Bank to Bedside: A Father’s Journey to Become a Catalyst for Change
Catalyst for Change: When former JPMorgan banker Ilan Ganot’s son was diagnosed with a rare form of muscular dystrophy, this father didn’t miss a beat to dedicate his life to saving his son’s.
Report: Roche Eyes $15B Financing Package to Acquire BioMarin
The U.S. drug maker's shares advanced only modestly as Roche denied having a need to raise cash.
Incyte To Stop Testing Jakafi in Some Cancers
Incyte Corp said it would discontinue some of the trials testing its already approved blood cancer drug, Jakafi, after the treatment's effectiveness was found to be insufficient.
AstraZeneca Sees 2016 Earnings Falling
AstraZeneca warned that revenue and earnings would drop this year due to the arrival of cheap generic rivals to its cholesterol fighter Crestor.
Walgreens Pulls Back From Theranos
Theranos Inc.'s main retail partner is suspending some ties to the blood-testing laboratory in the wake of a critical regulatory inspection report.
Bristol-Myers Forecasts '16 Profit Above Estimates
Bristol-Myers Squibb forecast 2016 earnings slightly above Wall Street estimates.
Report: Pfizer, Allergan Considering a Combination
Pfizer Inc and Allergan Plc are considering combining, the Wall Street Journal said on Wednesday.
Amgen Boosts Outlook as Profit Rises 50%
Amgen Inc. raised its 2015 guidance as the biotechnology company reported that its third-quarter earnings rose 50% on stronger revenue led by Enbrel and other key drugs.







